Wedbush Maintains a 'Neutral' on PetMed Express (PETS); Lowers Price Target
More News related to PETS
- Rosetta Stone Inc.'s Tom Adams Named Ernst & Young Entrepreneur of the Year(R) 2009 Overall National Winner
- PetMed Express D/B/A 1-800-PetMeds Announces Its Quarterly Dividend
- Wedbush Maintains a 'Neutral' on PetMed Express (PETS); Lowers Price Target
- Unusual 11 Mid-Day Movers 10/19: FIGI, IPCS, BEST, AMPL Higher; FNM, FRE, IDCC, PETS Lower
- PetMed (PETS) Shares Trade Lower This Morning on Lower Revenue
Wedbush maintains a 'Neutral' on PetMed Express (Nasdaq: PETS), lowers price target from $16 to $15.
Wedbush analyst says, "Once again (for the eleventh straight quarter), PETS reported inline or better than expected earnings. Management once again did not provide any financial guidance. PETS again effectively managed its advertising costs, spending less than expected on advertising ($7.8 million
compared with our estimate of $10.0 million) while still generating new customer growth of 233,000 versus our 260,000 estimate...We are maintaining our FY:10 estimate for revenue of $247 million, but raising our EPS estimate to $1.10 from $1.09 to reflect the upside in Q1."
To see more analyst ratings on PETS Click Here.
PetMed Express, Inc., doing business as 1-800-PetMeds, markets prescription and non-prescription pet medications; and other health products for dogs, cats, and horses direct to the consumer in the United States.
Related Categories
Analyst CommentsStocks Mentioned
-0.04Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
